NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa...
Q1 2026
Apr 1, 2026
FY 2025
Mar 31, 2026
Q4 2025
Q3 2025
Nov 14, 2025
Q2 2025
Aug 18, 2025